Cardiac adverse events associated with multiple myeloma patients treated with proteasome inhibitors

Researchers examined 1,567,240 cases of 231 drugs registered as anticancer drugs in the FDA Adverse Event Reporting System database, comparing the odds of developing cardiac adverse events between patients who received proteasome inhibitors and those who received non-PI anticancer drugs. They found that the safety signal for developing cardiac failure for bortezomib and carfilzomib did not differ between patients with and without concomitantly administered medications.